Literature DB >> 1602564

Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.

C L Kuiken1, J J de Jong, E Baan, W Keulen, M Tersmette, J Goudsmit.   

Abstract

The third variable domain (V3) of the envelope gene of human immunodeficiency virus type 1 contains a major neutralization epitope and determinants of syncytium-inducing (SI) capacity and replication rate (reviewed by J. P. Moore and P. L. Nara, AIDS Suppl. 2:S21-S33, 1991). Sequences were generated from DNA of samples taken 3 months apart over a period of 24 and 30 months from peripheral blood mononuclear cells (PBMC) of two individuals, both before and after cocultivation with uninfected donor PBMC. The isolated virus shifted from the non-syncytium-inducing (NSI) phenotype to the SI phenotype during the study period. This shift was associated with distinct changes in the V3 domain in both patients. The association of the phenotype shift with the V3 sequence changes was confirmed by construction of viruses with chimeric V3 loops. The shift from NSI- to SI-associated V3 variants was also seen in the uncultured PBMC of both patients, but not until 3 and 9 months after the detection of SI virus in culture. In the samples of uncultured PBMC DNA, several subgroups of sequences were found, indicating that the process of evolution may not be gradual and that several distinct populations can coexist. The paucity of intermediate sequences indicated that strong selection pressure was exerted on this part of the envelope. The early emergence of disease-associated SI variants in cultured material indicates that virus culture may have relevance for the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602564      PMCID: PMC241280     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  12 in total

Review 1.  The role of the V3 loop of gp120 in HIV infection.

Authors:  J P Moore; P L Nara
Journal:  AIDS       Date:  1991       Impact factor: 4.177

2.  Characterization of HIV-1 neutralization escape mutants.

Authors:  J A McKeating; J Gow; J Goudsmit; L H Pearl; C Mulder; R A Weiss
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

3.  Amino acid composition and the evolutionary rates of protein-coding genes.

Authors:  D Graur
Journal:  J Mol Evol       Date:  1985       Impact factor: 2.395

4.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Authors:  M Tersmette; R E de Goede; B J Al; I N Winkel; R A Gruters; H T Cuypers; H G Huisman; F Miedema
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

8.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

Authors:  J J de Jong; J Goudsmit; W Keulen; B Klaver; W Krone; M Tersmette; A de Ronde
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors:  L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  65 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.

Authors:  F Voulgaropoulou; B Tan; M Soares; B Hahn; L Ratner
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

6.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 10.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.